Evidence map›Paper›PMID 22410123›Full record

ReviewAtherosclerosis2012

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.

Doralisa Morrone, William S Weintraub, Peter P Toth, Mary E Hanson, Robert S Lowe, Jianxin Lin, Arvind K Shah, Andrew M Tershakovec

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Atherosclerosis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 104 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 10 pooled it
17.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04826354 phase4completedstarted 2021, after this paper: background citation

Effects of High-dose StAtin Versus Low-dose Statin Plus Ezetimibe on Statin-Associated Muscle Symptoms & on Reaching Target LDL-C Levels Among Elderly Patients With Atherosclerotic Cardiovascular Disease

Ran2021Enrolled582Registered outcomes11Posted comparisons0ConditionsAtheroscleroses, CoronaryArmsRosuvastatin, rosuvastatin and ezetimibe
PMID 30423391PMID 28249067PMID 30403574PMID 28007331PMID 28304224PMID 26039521PMID 28444290PMID 16453090PMID 22686958PMID 29020411PMID 30580575PMID 16214597other papers from this trial
Open the trial in the graph
NCT06767774 phase4recruitingstarted 2025, after this paper: background citation

Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus in Prediabetic Patients With Atherosclerotic Cardiovascular Disease

Ran2025Enrolled2,000Registered outcomes13Posted comparisons0ConditionsASCVD, Diabetes, StatinArmsCombination therapy, High intensity statin monotherapy
PMID 29263150PMID 23704171PMID 21693744PMID 20167359PMID 29718253PMID 30586774PMID 29165385PMID 28886621PMID 24239923PMID 17601626PMID 17559928PMID 12186811other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 10 syntheses or guidelines pooled it, 259 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. The promising novel therapies for familial hypercholesterolemia.Journal of clinical laboratory analysis · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2020
    Pooled it
  9. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Review

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Doralisa MorroneCardiology Section, Christiana Care Health System, Newark, DE 19718, United States. dory821101
William S Weintraub
Peter P Toth
Mary E Hanson
Robert S Lowe
Jianxin Lin
Arvind K Shah
Andrew M Tershakovec
Merck & Co., Inc., Rahway, NJ, USA (United States) · USChristiana Care Health System · USCGH Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePatients with dyslipoproteinemia constitute the largest risk group for development of atherosclerosis and cardiovascular disease (CVD). Despite extensive statin use, many patients with CVD risk do not achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets. This pooled analysis of 27 previously published clinical trials conducted between 1999 and 2008 evaluated the lipid-altering efficacy and factors related to treatment response of ezetimibe combined with statin and statin monotherapy.

methodsPatient-level data were combined from double-blind, placebo-controlled or active comparator studies randomizing adult subjects to ezetimibe 10mg plus statin (n=11,714) versus statin alone (n=10,517) for 6-24 weeks (mean=9 weeks). Association of factors with treatment response, percent change from baseline LDL-C and other lipids, and attainment of guideline-recommended lipid and lipoprotein targets were evaluated.

resultsHigher baseline LDL-C, diabetes mellitus, Black race, greater age, and male gender were associated with small but significantly greater percent reductions in LDL-C regardless of treatment. Treatment influenced efficacy, with ezetimibe plus statin producing significantly greater reductions in LDL-C, total-cholesterol, non-HDL-C, ApoB, triglycerides, lipid ratios, hs-CRP; significantly larger increases in HDL-C and ApoA1; and significantly higher achievement of LDL-C (<70mg/dl, <100mg/dl), non-HDL-C (<100mg/dl, <130mg/dl), and ApoB (<80mg/dl, <90mg/dl) targets than statin monotherapy at statin potencies compared (p<0.0001 for all). Differential treatment effects were seen with first-/second-line therapy and statin potency.

conclusionThese results suggest that patient characteristics have a limited influence on response to lipid-lowering therapy and demonstrate the consistent treatment effect of ezetimibe combined with statin and statin monotherapy across a diverse patient population.

Indexed as

AgedAnticholesteremic AgentsAzetidinesBiomarkersCholesterol, LDLClinical Trials as TopicDrug Therapy, CombinationEvidence-Based MedicineEzetimibeFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMaleMiddle AgedTreatment OutcomeAnticholesteremic AgentsAzetidinesBiomarkersCholesterol, LDLEzetimibeHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID22410123
OpenAlexW2052094004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.